EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?



Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?



Seminars in Thrombosis and Hemostasis 40(2): 269-270




(PDF emailed within 0-6 h: $19.90)

Accession: 055372459

Download citation: RISBibTeXText

PMID: 24500575

DOI: 10.1055/s-0034-1367471



Related references

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis 8(6): 1256-1265, 2010

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Critical Reviews in Oncology/Hematology 81(1): 82-93, 2012

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109(11): 4693-4697, 2007

Cost analysis of plasma-derived factor VIII/von Willebrand factor vs recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics: 1-16, 2018

Initial studies of genetic factors influencing inhibitor development in previously untreated patients with hemophilia treated with recombinant factor VIII. Blood 86(10 SUPPL 1): 610A, 1995

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 124(23): 3398-3408, 2015

Multicenter comparison of inhibitor development on plasma-derived vs recombinant factor VIII in severe hemophilia A patients. Blood 94(10 SUPPL 1 PART 1): 238a, Nov 15, 1999

French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis 80(5): 779-783, 1998

Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (RecombinateTM). Thrombosis and Haemostasis 83(6): 844-848, 2000

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. New England Journal of Medicine 328(7): 453-459, 1993

Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies. Journal of Thrombosis and Haemostasis 6(2): 390-392, 2007

Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies. Journal of Thrombosis and Haemostasis 6(2): 390-392, 2008

Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. International Journal of Hematology 62(1): 35-43, 1995

Clinical studies of recombinant factor VIII in previously untreated patients with severe hemophilia A. Blood 82(10 SUPPL 1): 446A, 1993

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Seminars in Thrombosis and Hemostasis 28(3): 285-290, 2002